Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01934556 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema
A Phase 1 study of Diabetic Macular Edema, sponsored by Palmetto Retina Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 3
- Study locations
NCT01934556 is a Phase 1 study of Diabetic Macular Edema that has completed, run by Palmetto Retina Center. The registered enrollment target is 150 participants, below the 3,792-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01934556, a Phase 1 study of Diabetic Macular Edema, has completed, sponsored by Palmetto Retina Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research study is to determine if a "Treat and Extend" regimen (increasing the time between visits when the disease is stable and not getting worse) of Ranibizumab 0.3 mg injections inside the eye is safe and effective at treating patients with swelling of the retina from diabetes.
Conditions Studied
Interventions
- DRUG Ranibizumab 0.3 mg intravitreal injection
- DEVICE Guided Laser Photocoagulation
Study Locations (3)
California
- Retina-Vitreous Associates Medical Group - Beverly Hills
South Carolina
- Palmetto Retina Center - West Columbia
Texas
- Retina Consultants of Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2013-11 |
| Est. Completion | 2018-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01934556
The ClinicalTrials.gov registry entry for NCT01934556 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,792-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (96% lower). The listed sponsor is Palmetto Retina Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Ranibizumab 0.3 mg intravitreal injection is the first listed.
NCT01934556 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, South Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT01934556 about?
NCT01934556 is a clinical study titled "A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema". The purpose of this research study is to determine if a "Treat and Extend" regimen (increasing the time between visits when the disease is stable and not getting worse) of Ranibizumab 0.3 mg injections inside the eye is safe and effective at treating patients with swelling of the retina from diabete...
What is the current status of trial NCT01934556?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2013-11. Estimated completion is 2018-04.
What conditions does trial NCT01934556 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT01934556?
The interventions under investigation include: Ranibizumab 0.3 mg intravitreal injection (DRUG), Guided Laser Photocoagulation (DEVICE).
Who is sponsoring clinical trial NCT01934556?
This trial is sponsored by Palmetto Retina Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01934556 being conducted?
This trial has 3 study locations across California, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
RECRUITING · Phase 1
-
Kamuvudine-9 (K9) in Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.